CTNX-4975

Phase 1Small molecule

CCentrexion Therapeutics

CTNX-4975 is one of 11 small molecule programs targeting Neuroma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuromaActive, not recruiting

NeuromaPhase 1

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Neuroma

#DrugCompanyPhaseTrials

IC-Green

CCHX Technologies Inc.

Approved

1 2

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—3

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Xylocaine

3 5

Medrol

Pfizer

Preclinical

2 6

Xylocaine

AstraZeneca

Phase 1

1 7

CNTX-4975

CCentrexion Therapeutics

Phase 2

2 8

ALGRX 4975

AAlgoRx Pharmaceuticals

Phase 2

1 9

Onabotulinum Toxin Type a

SSouthern Illinois University

Phase 2

1 10

Resiniferatoxin

SSorrento Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroma1 trial

Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Completed·CCentrexion Therapeutics·Phase 1·NCT02550756·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CTNX-4975. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CTNX-4975 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CTNX-4975. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centrexion Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCentrexion Therapeutics

CTNX-4975

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuroma1 trial

References

Drug Info

Quick Facts

Related News